Halozyme Therapeutics (NASDAQ:HALO) used an investor conference call to outline a series of strategic and financial updates, ...

Shortly after acquiring Elektrofi to beef up its subcutaneous drug-delivery offerings, Halozyme Therapeutics has struck ...

The Surf Bio acquisition comes shortly after Halozyme bought another company with a subcutaneous delivery technology, ...

In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. Aside from the $750 million upfront payment, the deal also ...

U.S. company Halozyme Therapeutics, regarded as a competitor to Korea's bio corporations Alteogen, will acquire Elektrofi, which has subcutaneous injection drug delivery technology, for up to $900 ...

SAN DIEGO, Nov. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the successful completion of its acquisition of Elektrofi, Inc. ("Elektrofi"), a ...

Halozyme's acquisition of Elektrofi includes the innovative Hypercon technology, enabling ultra-high concentration biologic formulations for improved drug delivery. The acquisition supports Halozyme's ...

SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) ("Halozyme") today announced it has entered into a definitive agreement to acquire Elektrofi, Inc. ("Elektrofi"), a ...

SAN DIEGO, Nov. 25, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host ...